Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CD30-
CD30 ligand
(
CD30L
) signal transduction appears to protect against autoimmune diabetes by preventing expansion of autoreactive T cells and suppressing Th1-cytokine response. The purpose of this study was to determine whether CD30 or
CD30L
genes serve as a novel susceptibility gene for
type 1 diabetes
in humans. We screened CD30 and
CD30L
genes for polymorphisms in Japanese patients with
type 1 diabetes
and control subjects. Then, association studies were performed between each of the identified polymorphisms and
type 1 diabetes
. Direct-sequencing analysis of the CD30 and
CD30L
genes revealed four polymorphisms: one in the CD30 gene (-201G/A from the transcription start site), and three in the
CD30L
gene [CA repeat in the promoter, 276G/A in the exon 3, -73T/C in the intron 3 (IVS3 -73T/C)]. Association studies revealed no association between the CD30 and
CD30L
genes and
type 1 diabetes
in the whole population. In the female and male subpopulations, however, the frequency of (CA)(9) allele of the
CD30L
gene promoter or T allele of IVS3 -73T/C polymorphism in the
CD30L
gene was slightly higher in female patients with
type 1 diabetes
than that in control females. In conclusion, we could not find significant association between CD30 or
CD30L
genes and
type 1 diabetes
, but (CA)(9) allele in the promotor or T allele of -73T/C in intron 3 in
CD30L
gene might play a minor role in the pathogenesis of
type 1 diabetes
, only in the Japanese female population.
...
PMID:Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population. 1196 Mar 7